Searching in Pharma & Drug Safety · Search everything
3,019 changes Pharma & Drug Safety
Tricyclic KRAS Inhibitor Patent - Incyte Corporation
The USPTO granted Patent US12600717B2 to Incyte Corporation on April 14, 2026 for tricyclic compounds as inhibitors of KRAS activity. The patent contains 34 claims covering Formula I compounds useful in treating diseases associated with KRAS activity, including cancer. Filing date was July 13, 2022, under application number 17812310.
Salt Inducible Kinase Inhibitors Patent Granted to General Hospital Corporation
USPTO granted patent US12600719B2 to General Hospital Corporation covering salt inducible kinase (SIK) inhibitor compounds and pharmaceutical compositions. Inventors Marc Nathan Wein and William J. Greenlee filed the application on August 5, 2021. The patent contains 20 claims under CPC classification C07D 471/04.
Modified Double-Stranded Oligonucleotide Patent - Alnylam Pharmaceuticals
USPTO granted patent US12600965B2 to Alnylam Pharmaceuticals, Inc. covering modified double-stranded RNA (dsRNA) agents capable of inhibiting target gene expression. The patent, filed November 5, 2019, includes 38 claims and covers pharmaceutical compositions comprising these dsRNA molecules for therapeutic applications. Inventors include Donald Foster, Mark K. Schlegel, and Christopher Brown.
Replication-Competent Recombinant HSV-1 With ICP6/IR Deletions for Cancer Treatment
USPTO granted Patent US12600955B1 to Sungkwang Medical Foundation for a replication-competent recombinant herpes simplex virus type 1 (HSV-1) with simultaneous deletions in the ICP6 and IR regions. The patent covers the recombinant HSV-1, vector, and methods of preparation for cancer treatment as an oncolytic virus. The invention enables larger foreign gene insertion and simultaneous multiple gene insertion while maintaining safety and cancer cell killing efficacy.
Cell Reprogramming Patent, Asgard Therapeutics, 14th Apr
Cell Reprogramming Patent, Asgard Therapeutics, 14th Apr
Viral and Non-Viral Nanoplasmid Vectors with Improved Production
USPTO granted patent US12600984B2 to Aldevron, L.L.C. covering methods for improving replication of covalently closed circular plasmids through replacement of Pol I-dependent origins with Pol III-dependent origins. The patent also claims antibiotic marker free covalently closed circular recombinant DNA molecules. The patent contains 31 claims.
Compositions and Methods for Controlling Production of Polypeptides in Cells
USPTO granted Patent US12600985B2 to the Board of Trustees of the Leland Stanford Junior University on April 14, 2026. The patent covers recombinant expression vectors with coding sequences flanked by recombinase recognition sites for modulating polypeptide production in target cells, along with associated methods and monitoring devices. Inventors include Karl A. Deisseroth, Charu Ramakrishnan, Yoon Seok Kim, and Lief E. Fenno. The patent contains 25 claims under CPC Classification C12N 15/85.
Washington University Patent for Toxoplasma Gondii Treatment Compounds
The USPTO granted Patent US12600727B2 to Washington University on April 14, 2026, covering compounds and methods for treating infections caused by Toxoplasma gondii and related parasites. The patent includes 18 claims and lists inventors L. David Sibley, Joshua Radke, Eamon Comer, Marshall Morningstar, and Bruno Melillo. This grant provides Washington University with exclusive intellectual property rights for the developed antiparasitic compounds and their pharmaceutical applications.
Interleukin-17 Inhibitors Patent - Novartis AG
The USPTO granted patent US12600728B2 to NOVARTIS AG covering novel pyridine-N oxide substituted 2-formamido (N-phenyl and N-pyridyl) acetamide compounds as Interleukin-17 (IL-17) inhibitors. The patent also protects processes for preparing these compounds, pharmaceutical compositions, and medicaments for treating diseases and disorders mediated by IL-17.
Vanderbilt Cyclopropylpiperidine M4 Antagonists - US12600726B2
The USPTO granted Patent No. US12600726B2 to Vanderbilt University on April 14, 2026, covering cyclopropylpiperidine compounds useful as antagonists of muscarinic acetylcholine receptor M4 (mAChR M4). The patent includes 15 claims and covers methods of making the compounds, pharmaceutical compositions, and methods of treating disorders using the compounds. Vanderbilt University receives enforceable IP rights for this therapeutic compound class.